Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT02005289Phase 2Completed
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic Leukemia+9 more
PrincipalinvestigatorStart date: 2014-01-17

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ryotaro Nakamura

City of Hope Medical Center

Moderately Similar
10 trials

Shared therapeutic areas:

Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaLeukemia, Prolymphocytic+9 more
Similarity Score30%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Moderately Similar
11 trials

Shared therapeutic areas:

Recurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaLeukemia, Prolymphocytic+9 more
Similarity Score30%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Refractory Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaStage I Small Lymphocytic Lymphoma+4 more
Similarity Score18%

Leona Holmberg

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Noncontiguous Stage II Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+4 more
Similarity Score18%

Srdan Verstovsek

M.D. Anderson Cancer Center

Related
4 trials

Shared therapeutic areas:

Leukemia, ProlymphocyticRefractory Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic Leukemia+3 more
Similarity Score15%

Sikander Ailawadhi, M.D.

Mayo Clinic

Related
6 trials

Shared therapeutic areas:

Recurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic Leukemia+3 more
Similarity Score15%

Noelle Frey, MD

Abramson Cancer Center at Penn Medicine

Related
7 trials

Shared therapeutic areas:

Leukemia, ProlymphocyticRefractory Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score10%

Charles Erlichman

Mayo Clinic

Related
6 trials

Shared therapeutic areas:

Recurrent Small Lymphocytic LymphomaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic Lymphoma
Similarity Score8%

chitra hosing

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Leukemia, ProlymphocyticRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
Similarity Score8%

Brenda Sandmaier

Fred Hutch/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Refractory Chronic Lymphocytic LeukemiaLeukemia, ProlymphocyticRecurrent Small Lymphocytic Lymphoma
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT02005289Phase 2PrincipalInvestigator

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic Leukemia+9 more
Completed

All 1 trials loaded